International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

ser



Downloads: 3 | Views: 130 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Ophthalmology | India | Volume 11 Issue 3, March 2022 | Rating: 5.1 / 10


Ophthalmic Complications of COVID-19 Infection at a Tertiary Care Centre in Kashmir Valley

Zainab Haroon Jan | Iqra Ali


Abstract: Purpose: To study the ophthalmic complications of COVID-19 infection at a tertiary care centre in Kashmir Valley. Method: This study was a cross sectional observational, hospital-based study over a period of 1 year from April 2020 to May 2020. 500 lab diagnosed covid-19 positive patients above the age of 15 were included in the study. Result: In our study of 500 patients with COVID-19 infection.51 (10.2%) had ocular manifestations. Majority of the patients were females (54.9%). Most of the patients were of the age group 15-44 (50.9%). Mean duration of conjunctival congestion was 5.3?2.8. Mean duration between appearance of clinical symptoms and conjunctival congestion was 11.6?5.9. Out of 51 patients with ocular manifestations 51 patients had conjunctivitis, 15 patients (29.4%) had keratoconjunctivitis.10 patients (19.6%) had vitreous haemorrhage.6 patients (11.7%) had central retinal venous occlusion.1 patient (1.9%) had central retinal artery occlusion. Ophthalmic sequalae was seen in 1 patient in the form of CRAO, Rest of the patients had complete recovery without any ophthalmic complaint. Conclusion: Mild conjunctivitis manifesting as conjunctival congestion is common and is one of the major ocular manifestations in COVID-19 positive patients.


Keywords: COVID-19, conjunctivitis, keratoconjuctivitis, photophobia, vitreous haemorrhage


Edition: Volume 11 Issue 3, March 2022,


Pages: 1298 - 1300


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top